Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract.

International journal of integrated care

H H, C H, R K, M RR, A S, W W.
PMID: 20689772
Int J Integr Care. 2010 Jun 23;10:e046. doi: 10.5334/ijic.539.

INTRODUCTION: Integrated care solutions need supportive financial incentives. In this paper, we describe the financial architecture and operative details of the integrated pilot Gesundes Kinzigtal.DESCRIPTION OF INTEGRATED CARE CASE: Located in Southwest Germany, Gesundes Kinzigtal is one of the...

Cite
H H, C H, R K, et al. Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. Int J Integr Care. 2010;10:e046doi: 10.5334/ijic.539.
H, H., C, H., R, K., M, R. R., A, S., & W, W. (2010). Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. International journal of integrated care, 10e046. https://doi.org/10.5334/ijic.539
H, Hildebrandt, et al. "Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract." International journal of integrated care vol. 10 (2010): e046. doi: https://doi.org/10.5334/ijic.539
H H, C H, R K, M RR, A S, W W. Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. Int J Integr Care. 2010 Jun 23;10:e046. doi: 10.5334/ijic.539. PMID: 20689772; PMCID: PMC2914874.
Copy Download .nbib Format: NLM
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19.

Blood advances

Wygrecka M, Birnhuber A, Seeliger B, Michalick L, Pak O, Schultz AS, Schramm F, Zacharias M, Gorkiewicz G, David S, Welte T, Schmidt JJ, Weissmann N, Schermuly RT, Barreto G, Schaefer L, Markart P, Brack MC, Hippenstiel S, Kurth F, Sander L, Witzenrath M, Kuebler W, Kwapiszewska G, Preissner KT.
PMID: 34861681
Blood Adv. 2021 Dec 03; doi: 10.1182/bloodadvances.2021004816. Epub 2021 Dec 03.

The high incidence of thrombotic events suggests a possible role of the contact system pathway in COVID-19 pathology. Here, we demonstrate altered levels of factor XII (FXII) and its activation products in critically ill COVID-19 patients in comparison to...

Cite
Wygrecka M, Birnhuber A, Seeliger B, et al. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood Adv. 2021;doi: 10.1182/bloodadvances.2021004816.
Wygrecka, M., Birnhuber, A., Seeliger, B., Michalick, L., Pak, O., Schultz, A. S., Schramm, F., Zacharias, M., Gorkiewicz, G., David, S., Welte, T., Schmidt, J. J., Weissmann, N., Schermuly, R. T., Barreto, G., Schaefer, L., Markart, P., Brack, M. C., Hippenstiel, S., Kurth, F., Sander, L., Witzenrath, M., Kuebler, W., Kwapiszewska, G., & Preissner, K. T. (2021). Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood advances, . https://doi.org/10.1182/bloodadvances.2021004816
Wygrecka, Malgorzata, et al. "Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19." Blood advances vol. (2021). doi: https://doi.org/10.1182/bloodadvances.2021004816
Wygrecka M, Birnhuber A, Seeliger B, Michalick L, Pak O, Schultz AS, Schramm F, Zacharias M, Gorkiewicz G, David S, Welte T, Schmidt JJ, Weissmann N, Schermuly RT, Barreto G, Schaefer L, Markart P, Brack MC, Hippenstiel S, Kurth F, Sander L, Witzenrath M, Kuebler W, Kwapiszewska G, Preissner KT. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19. Blood Adv. 2021 Dec 03; doi: 10.1182/bloodadvances.2021004816. Epub 2021 Dec 03. PMID: 34861681; PMCID: PMC8648369.
Copy Download .nbib Format: NLM
Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.

Respiratory medicine

Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D, Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T, Witzenrath M, Zoller T.
PMID: 34871947
Respir Med. 2021 Dec 01;191:106709. doi: 10.1016/j.rmed.2021.106709. Epub 2021 Dec 01.

INTRODUCTION: Prospective and longitudinal data on pulmonary injury over one year after acute coronavirus disease 2019 (COVID-19) are sparse. We aim to determine reductions in pulmonary function and respiratory related quality of life up to 12 months after acute...

Cite
Steinbeis F, Thibeault C, Doellinger F, et al. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2021;191:106709doi: 10.1016/j.rmed.2021.106709.
Steinbeis, F., Thibeault, C., Doellinger, F., Ring, R. M., Mittermaier, M., Ruwwe-Glösenkamp, C., Alius, F., Knape, P., Meyer, H. J., Lippert, L. J., Helbig, E. T., Grund, D., Temmesfeld-Wollbrück, B., Suttorp, N., Sander, L. E., Kurth, F., Penzkofer, T., Witzenrath, M., & Zoller, T. (2021). Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respiratory medicine, 191106709. https://doi.org/10.1016/j.rmed.2021.106709
Steinbeis, Fridolin, et al. "Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months." Respiratory medicine vol. 191 (2021): 106709. doi: https://doi.org/10.1016/j.rmed.2021.106709
Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D, Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T, Witzenrath M, Zoller T. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2021 Dec 01;191:106709. doi: 10.1016/j.rmed.2021.106709. Epub 2021 Dec 01. PMID: 34871947; PMCID: PMC8632363.
Copy Download .nbib Format: NLM
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids.

Clinical lung cancer

Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C.
PMID: 33648877
Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 06.

INTRODUCTION: Pembrolizumab is a highly effective standard of care in PD-L1 overexpressing (≥ 50%) non-small-cell lung cancer. However, a substantial share of patients from everyday clinical practice is treated without clear evidence from clinical trials.PATIENTS AND METHODS: We performed...

Cite
Frost N, Kollmeier J, Misch D, et al. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clin Lung Cancer. 2021;22(5):411-422doi: 10.1016/j.cllc.2021.02.001.
Frost, N., Kollmeier, J., Misch, D., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., Olive, E., Raspe, M., Ochsenreither, S., von Laffert, M., Suttorp, N., Witzenrath, M., & Grohé, C. (2021). Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clinical lung cancer, 22(5), 411-422. https://doi.org/10.1016/j.cllc.2021.02.001
Frost, Nikolaj, et al. "Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids." Clinical lung cancer vol. 22,5 (2021): 411-422. doi: https://doi.org/10.1016/j.cllc.2021.02.001
Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 06. PMID: 33648877.
Copy Download .nbib Format: NLM
Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure.

Cells

Letsiou E, Teixeira Alves LG, Felten M, Mitchell TJ, Müller-Redetzky HC, Dudek SM, Witzenrath M.
PMID: 34944089
Cells. 2021 Dec 18;10(12). doi: 10.3390/cells10123581.

Pneumolysin (PLY) is a pore-forming toxin of

Cite
Letsiou E, Teixeira Alves LG, Felten M, et al. Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells. 2021;10(12)doi: 10.3390/cells10123581.
Letsiou, E., Teixeira Alves, L. G., Felten, M., Mitchell, T. J., Müller-Redetzky, H. C., Dudek, S. M., & Witzenrath, M. (2021). Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells, 10(12), . https://doi.org/10.3390/cells10123581
Letsiou, Eleftheria, et al. "Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure." Cells vol. 10,12 (2021). doi: https://doi.org/10.3390/cells10123581
Letsiou E, Teixeira Alves LG, Felten M, Mitchell TJ, Müller-Redetzky HC, Dudek SM, Witzenrath M. Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells. 2021 Dec 18;10(12). doi: 10.3390/cells10123581. PMID: 34944089.
Copy Download .nbib Format: NLM
Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure.

Cells

Letsiou E, Teixeira Alves LG, Felten M, Mitchell TJ, Müller-Redetzky HC, Dudek SM, Witzenrath M.
PMID: 34944089
Cells. 2021 Dec 18;10(12). doi: 10.3390/cells10123581.

Pneumolysin (PLY) is a pore-forming toxin of

Cite
Letsiou E, Teixeira Alves LG, Felten M, et al. Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells. 2021;10(12)doi: 10.3390/cells10123581.
Letsiou, E., Teixeira Alves, L. G., Felten, M., Mitchell, T. J., Müller-Redetzky, H. C., Dudek, S. M., & Witzenrath, M. (2021). Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells, 10(12), . https://doi.org/10.3390/cells10123581
Letsiou, Eleftheria, et al. "Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure." Cells vol. 10,12 (2021). doi: https://doi.org/10.3390/cells10123581
Letsiou E, Teixeira Alves LG, Felten M, Mitchell TJ, Müller-Redetzky HC, Dudek SM, Witzenrath M. Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure. Cells. 2021 Dec 18;10(12). doi: 10.3390/cells10123581. PMID: 34944089; PMCID: PMC8700313.
Copy Download .nbib Format: NLM
Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01.

EClinicalMedicine

Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B.
PMID: 34490415
EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02.

BACKGROUND: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen...

Cite
Weiner J, Suwalski P, Holtgrewe M, et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021;40:101099doi: 10.1016/j.eclinm.2021.101099.
Weiner, J., Suwalski, P., Holtgrewe, M., Rakitko, A., Thibeault, C., Müller, M., Patriki, D., Quedenau, C., Krüger, U., Ilinsky, V., Popov, I., Balnis, J., Jaitovich, A., Helbig, E. T., Lippert, L. J., Stubbemann, P., Real, L. M., Macías, J., Pineda, J. A., Fernandez-Fuertes, M., Wang, X., Karadeniz, Z., Saccomanno, J., Doehn, J. M., Hübner, R. H., Hinzmann, B., Salvo, M., Blueher, A., Siemann, S., Jurisic, S., Beer, J. H., Rutishauser, J., Wiggli, B., Schmid, H., Danninger, K., Binder, R., Corman, V. M., Mühlemann, B., Arjun Arkal, R., Fragiadakis, G. K., Mick, E., Comet, C., Calfee, C. S., Erle, D. J., Hendrickson, C. M., Kangelaris, K. N., Krummel, M. F., Woodruff, P. G., Langelier, C. R., Venkataramani, U., García, F., Zyla, J., Drosten, C., Alice, B., Jones, T. C., Suttorp, N., Witzenrath, M., Hippenstiel, S., Zemojtel, T., Skurk, C., Poller, W., Borodina, T., Pa-Covid, S. G., Ripke, S., Sander, L. E., Beule, D., Landmesser, U., Guettouche, T., Kurth, F., & Heidecker, B. (2021). Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 40101099. https://doi.org/10.1016/j.eclinm.2021.101099
Weiner, January, et al. "Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01." EClinicalMedicine vol. 40 (2021): 101099. doi: https://doi.org/10.1016/j.eclinm.2021.101099
Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 02. PMID: 34490415; PMCID: PMC8410317.
Copy Download .nbib Format: NLM
A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae.

Vaccine

Kaplonek P, Yao L, Reppe K, Voß F, Kohler T, Ebner F, Schäfer A, Blohm U, Priegue P, Bräutigam M, Pereira CL, Parameswarappa SG, Emmadi M, Ménová P, Witzenrath M, Hammerschmidt S, Hartmann S, Sander LE, Seeberger PH.
PMID: 35033388
Vaccine. 2022 Jan 13; doi: 10.1016/j.vaccine.2021.12.068. Epub 2022 Jan 13.

Streptococcus pneumoniae (S. pneumoniae)infections are the leading cause of child mortality globally. Currentvaccines fail to induceaprotective immune response towards a conserved part of the pathogen,resulting in newserotypescausing disease. Therefore, new vaccinestrategies are urgently needed.Described is atwo-pronged approach combiningS. pneumoniaeproteins,...

Cite
Kaplonek P, Yao L, Reppe K, et al. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. 2022;doi: 10.1016/j.vaccine.2021.12.068.
Kaplonek, P., Yao, L., Reppe, K., Voß, F., Kohler, T., Ebner, F., Schäfer, A., Blohm, U., Priegue, P., Bräutigam, M., Pereira, C. L., Parameswarappa, S. G., Emmadi, M., Ménová, P., Witzenrath, M., Hammerschmidt, S., Hartmann, S., Sander, L. E., & Seeberger, P. H. (2022). A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine, . https://doi.org/10.1016/j.vaccine.2021.12.068
Kaplonek, Paulina, et al. "A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae." Vaccine vol. (2022). doi: https://doi.org/10.1016/j.vaccine.2021.12.068
Kaplonek P, Yao L, Reppe K, Voß F, Kohler T, Ebner F, Schäfer A, Blohm U, Priegue P, Bräutigam M, Pereira CL, Parameswarappa SG, Emmadi M, Ménová P, Witzenrath M, Hammerschmidt S, Hartmann S, Sander LE, Seeberger PH. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. 2022 Jan 13; doi: 10.1016/j.vaccine.2021.12.068. Epub 2022 Jan 13. PMID: 35033388.
Copy Download .nbib Format: NLM
[Rare pulmonary infections].

Der Pneumologe

Witzenrath M.
PMID: 32904629
Pneumologe (Berl). 2020;17(5):299-300. doi: 10.1007/s10405-020-00334-5. Epub 2020 Aug 31.

No abstract available.

Cite
Witzenrath M. Seltene pulmonale Infektionen. [Rare pulmonary infections]. Pneumologe (Berl). 2020;17(5):299-300doi: 10.1007/s10405-020-00334-5.
Witzenrath, M. (2020). Seltene pulmonale Infektionen. [Rare pulmonary infections]. Der Pneumologe, 17(5), 299-300. https://doi.org/10.1007/s10405-020-00334-5
Witzenrath, Martin. "Seltene pulmonale Infektionen." [Rare pulmonary infections]. Der Pneumologe vol. 17,5 (2020): 299-300. doi: https://doi.org/10.1007/s10405-020-00334-5
Witzenrath M. Seltene pulmonale Infektionen. [Rare pulmonary infections]. Pneumologe (Berl). 2020;17(5):299-300. doi: 10.1007/s10405-020-00334-5. Epub 2020 Aug 31. German. PMID: 32904629; PMCID: PMC7457896.
Copy Download .nbib Format: NLM
Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.

Respiratory medicine

Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D, Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T, Witzenrath M, Zoller T.
PMID: 34871947
Respir Med. 2021 Dec 01;191:106709. doi: 10.1016/j.rmed.2021.106709. Epub 2021 Dec 01.

INTRODUCTION: Prospective and longitudinal data on pulmonary injury over one year after acute coronavirus disease 2019 (COVID-19) are sparse. We aim to determine reductions in pulmonary function and respiratory related quality of life up to 12 months after acute...

Cite
Steinbeis F, Thibeault C, Doellinger F, et al. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2021;191:106709doi: 10.1016/j.rmed.2021.106709.
Steinbeis, F., Thibeault, C., Doellinger, F., Ring, R. M., Mittermaier, M., Ruwwe-Glösenkamp, C., Alius, F., Knape, P., Meyer, H. J., Lippert, L. J., Helbig, E. T., Grund, D., Temmesfeld-Wollbrück, B., Suttorp, N., Sander, L. E., Kurth, F., Penzkofer, T., Witzenrath, M., & Zoller, T. (2021). Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respiratory medicine, 191106709. https://doi.org/10.1016/j.rmed.2021.106709
Steinbeis, Fridolin, et al. "Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months." Respiratory medicine vol. 191 (2021): 106709. doi: https://doi.org/10.1016/j.rmed.2021.106709
Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glösenkamp C, Alius F, Knape P, Meyer HJ, Lippert LJ, Helbig ET, Grund D, Temmesfeld-Wollbrück B, Suttorp N, Sander LE, Kurth F, Penzkofer T, Witzenrath M, Zoller T. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2021 Dec 01;191:106709. doi: 10.1016/j.rmed.2021.106709. Epub 2021 Dec 01. PMID: 34871947; PMCID: PMC8632363.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.

Cell

Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D, Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE.
PMID: 34914922
Cell. 2021 Nov 27; doi: 10.1016/j.cell.2021.11.033. Epub 2021 Nov 27.

COVID-19-induced "acute respiratory distress syndrome" (ARDS) is associated with prolonged respiratory failure and high mortality, but the mechanistic basis of lung injury remains incompletely understood. Here, we analyze pulmonary immune responses and lung pathology in two cohorts of patients...

Cite
Wendisch D, Dietrich O, Mari T, et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;doi: 10.1016/j.cell.2021.11.033.
Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C., Chua, R. L., Knoll, R., Timm, S., Brumhard, S., Krammer, T., Zauber, H., Hiller, A. L., Pascual-Reguant, A., Mothes, R., Bülow, R. D., Schulze, J., Leipold, A. M., Djudjaj, S., Erhard, F., Geffers, R., Pott, F., Kazmierski, J., Radke, J., Pergantis, P., Baßler, K., Conrad, C., Aschenbrenner, A. C., Sawitzki, B., Landthaler, M., Wyler, E., Horst, D., Hippenstiel, S., Hocke, A., Heppner, F. L., Uhrig, A., Garcia, C., Machleidt, F., Herold, S., Elezkurtaj, S., Thibeault, C., Witzenrath, M., Cochain, C., Suttorp, N., Drosten, C., Goffinet, C., Kurth, F., Schultze, J. L., Radbruch, H., Ochs, M., Eils, R., Müller-Redetzky, H., Hauser, A. E., Luecken, M. D., Theis, F. J., Conrad, C., Wolff, T., Boor, P., Selbach, M., Saliba, A. E., & Sander, L. E. (2021). SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, . https://doi.org/10.1016/j.cell.2021.11.033
Wendisch, Daniel, et al. "SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis." Cell vol. (2021). doi: https://doi.org/10.1016/j.cell.2021.11.033
Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D, Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021 Nov 27; doi: 10.1016/j.cell.2021.11.033. Epub 2021 Nov 27. PMID: 34914922; PMCID: PMC8626230.
Copy Download .nbib Format: NLM
SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.

Cell

Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D, Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE.
PMID: 34914922
Cell. 2021 Nov 27; doi: 10.1016/j.cell.2021.11.033. Epub 2021 Nov 27.

COVID-19-induced "acute respiratory distress syndrome" (ARDS) is associated with prolonged respiratory failure and high mortality, but the mechanistic basis of lung injury remains incompletely understood. Here, we analyze pulmonary immune responses and lung pathology in two cohorts of patients...

Cite
Wendisch D, Dietrich O, Mari T, et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;doi: 10.1016/j.cell.2021.11.033.
Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C., Chua, R. L., Knoll, R., Timm, S., Brumhard, S., Krammer, T., Zauber, H., Hiller, A. L., Pascual-Reguant, A., Mothes, R., Bülow, R. D., Schulze, J., Leipold, A. M., Djudjaj, S., Erhard, F., Geffers, R., Pott, F., Kazmierski, J., Radke, J., Pergantis, P., Baßler, K., Conrad, C., Aschenbrenner, A. C., Sawitzki, B., Landthaler, M., Wyler, E., Horst, D., Hippenstiel, S., Hocke, A., Heppner, F. L., Uhrig, A., Garcia, C., Machleidt, F., Herold, S., Elezkurtaj, S., Thibeault, C., Witzenrath, M., Cochain, C., Suttorp, N., Drosten, C., Goffinet, C., Kurth, F., Schultze, J. L., Radbruch, H., Ochs, M., Eils, R., Müller-Redetzky, H., Hauser, A. E., Luecken, M. D., Theis, F. J., Conrad, C., Wolff, T., Boor, P., Selbach, M., Saliba, A. E., & Sander, L. E. (2021). SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, . https://doi.org/10.1016/j.cell.2021.11.033
Wendisch, Daniel, et al. "SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis." Cell vol. (2021). doi: https://doi.org/10.1016/j.cell.2021.11.033
Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D, Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021 Nov 27; doi: 10.1016/j.cell.2021.11.033. Epub 2021 Nov 27. PMID: 34914922.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries